Healthcare

Andrew Aijian is a Partner at DeciBio Consulting, where he leads the biopharma business practice. DeciBio is a leading precision medicine consulting firm, with the mission to leverage market insights and strategy to drive disruption and innovation in precision medicine. DeciBio’s expertise in innovation is widely recognized, as evidenced by its #3 rating on Vault’s “Best Consulting Firms for Innovation” list in 2022. Aijian specializes in helping precision medicine companies understand how to leverage the latest research, diagnostic, and digital technologies in their R&D and commercialization strategies to improve patient care today and in the future. Aijian has been sought out as an early advisor on some of the most pivotal developments in cancer care, including cancer immunotherapies and early cancer detection technologies. As a partner at a rapidly growing, boutique firm, Aijian wears many hats, including leading DeciBio’s marketing and PR efforts, as well as driving the development of various database, market report, and SaaS products within DeciBio’s market intelligence and data analytics division, DeciBio Analytics. Prior to DeciBio, Aijian received his Ph.D. in biomedical engineering at UCLA.

SDG Group is proud to have Alejandro Martínez serve in many diverse capacities within its healthcare and life sciences sector. In addition to his longstanding title of Partner, Martínez is Chief Executive Officer in the company’s United States and Canada division, and he heads SDG’s global clients organization from its offices in Barcelona. A world-class executive who has earned international industry recognition for his leadership and insights in data analytics, he has served on the Forbes Business Council and held professorships with his alma mater and ESTEMA Escuela de Negocios. Martínez holds multiple degrees in project management and international business from Universitat Politècnica de València.

Andrew Kadar is a Managing Director and Partner in L.E.K. Consulting’s Private Equity practice and Healthcare Services practice. Andrew is based in the firm’s San Francisco office. He joined L.E.K. in 2006 as an associate and advises private equity investors as well as healthcare payers, providers, and HCIT firms on critical strategic issues. His core areas of expertise include buy-side due diligence, sell-side support, and portfolio company growth strategy and operations improvement. Andrew’s expert commentary has appeared in Health Leaders and Forbes. Andrew holds a Bachelor of Arts degree in economics from the University of California, Berkeley, and a Master of Business Administration from Harvard Business School. In 2016, Andrew was selected as a Rising Star of the Consulting Profession by Consulting magazine, and in 2020, he received an Emerging Leaders award from The M&A Advisor.

Avi Kulkarni leads Cognizant’s global life sciences. He is responsible for commercial development, planning, and P&L execution for Cognizant’s biopharma and medical device clients across research and development, commercial, and digital functions. Kulkarni has been at the forefront of the drugs and diagnostics industry for over three decades, building new drug formulations, launching new diagnostic tests, publishing extensively in personalized medicine, and building capabilities in cellular therapies. Prior to joining Cognizant in June 2021, he served as managing director and head of Accenture’s global clinical business, where he drove double-digit annual growth. Before Accenture, Kulkarni was SVP and leader of IQVIA, a clinical research organization. Previously, he was global head of life sciences R&D at Booz & Co., a management consulting company. He also held CXO roles at three biotechnology start-ups spun out from Stanford University and funded by Sand Hill Road venture capital. Kulkarni is a pharmacist who holds a Ph.D. degree in pharmaceutics from Temple University, Pennsylvania, and a Master of Business Administration from Stanford University. He has been a San Francisco bay area resident for nearly three decades, where he currently lives with his wife and daughter.

Ben Enejo is a Partner at Arthur D. Little, based in the company’s Boston office, and a member of its global Healthcare & Life Sciences practice. Enejo is an experienced management consultant and industry expert, having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through commercialization. His particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence. Prior to joining Arthur D. Little, Enejo was a managing consultant at PA Consulting Group where he supported various pharmaceutical, biotech, and clinical research organizations on various transformation initiatives. He also held industry roles in pharma development before moving into management consultancy. Enejo holds a Master of Business Administration from Cranfield School of Management plus other qualifications in Molecular Medicine (MSc), Pharmacology and Physiology (BSc), and Program Management.

Brad Michel is the North American Industry Lead for Life Sciences at Accenture, a global professional services company with leading capabilities in digital, cloud, and security. Accenture combines unmatched experience and specialized skills across more than 40 industries to deliver services in strategy and consulting, technology, operations, and Accenture Song, all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. As the Life Sciences Industry Lead, Michel is responsible for driving Accenture’s strategy and offerings to lead change for the industry’s most critical issues. His portfolio includes the biopharma/biotech, medtech, wholesaler/distributor industry segments, and knitting together talent and solutions across the value chain (R&D, Sales & Marketing, Supply Chain & Manufacturing, IT and enabling functions) for the benefit of Accenture’s clients. Michel boasts greater than 2 decades of experience in life sciences, including responsibility for leading large client relationships with Top 10 pharmaceutical companies, with a focus on driving growth and transformation through innovation, technology and operational efficiency. In addition, he has significant global experience and a broad background in business advisory and management consulting, digital transformation, and outsourcing operations. He holds a bachelor’s degree in computer science from Villanova University.

Bob Serrano is a Managing Partner at Kx Advisors, a growth strategy healthcare consulting firm. With offices in the U.S. and U.K., Kx Advisors excels in building new market strategies for pharmaceuticals, medical devices, diagnostics, and digital health. Serrano brings over 20 years of experience to clients ranging from startups to large, multinational companies, specializing in strategic planning, product development, and commercial launch. Prior to Kx, Serrano was a senior vice president of Kaiser Associates’ Healthcare Practice, which he co-launched into Kx Advisors in 2019. Earlier in his career, Serrano led North American laboratory marketing for QIAGEN’s molecular diagnostics business, and held several strategy and commercial roles in Abbott’s pharmaceutical products division (now AbbVie). Serrano earned a Master of Business Administration from the Kellogg School of Management at Northwestern University, a master’s in health administration, and a Bachelor’s of Science in nutritional science from Cornell University.

Managing Director of the Healthcare Sector David Krahe brings more than twenty years of leadership experience to his work with Russell Reynolds Associates. In his capacity as an executive as well as advisor to the company’s board and CEO, he contributes his diverse experience to Fortune 500 companies and emerging stars working in global healthcare and medtech around the world. His vast and varied experience in the field includes six years as director of product marketing with St. Jude Medical and nine years as Lieutenant, nuclear engineer, and assistant weapons officer with the U.S. Navy. Krahe holds a bachelor’s degree in naval architecture and marine engineering from the United States Naval Academy.

Paul Schrimpf is more than a Partner at Chicago consultancy Prophet; he is a member of the company’s major North American Leadership Team, supervises its healthcare practice, and oversees all its various sub-sectors, ranging from medical equipment to hospital systems and beyond. In addition, he is a long-serving board member of nonprofit initiative The Water Trust, a strategic advisor at ScaleHealth, and the host of the healthcare industry podcast Microdosing. Schrimpf holds a bachelor’s degree in marketing and accounting from Loyola University Chicago and a master’s in marketing research from Southern Illinois University Edwardsville.

Sarah Ladd Eames is a senior member of the Board and CEO Advisory Group, as well as the Health Services and Global Life Sciences Practices at Russell Reynolds Associates. She specializes in succession planning and recruiting CEOs, senior executive leaders, and board members for healthcare services, health plans, pharmaceutical, and diagnostics companies. Eames serves a diverse group of clients comprised of Fortune 500, mid-cap, and emerging growth companies in the United States and Europe. She has recruited for multisite for-profit and private equity healthcare services companies, managed care organizations, and integrated delivery systems. Based in New York, she offers clients a broad industry perspective, strategic insights, a consultative approach, and rigorous assessment of candidates. Eames also co-founded the firm’s CEO Roundtable for Healthcare CEOs. Eames possesses more than 25 years of diverse healthcare services and board of director experience in both the public and private sectors, including time with Trinity Health. Prior to joining RRA, Eames held roles at Allied Healthcare International, and also held roles at American Hospital Supply Corporation, Apria Healthcare Group, Baxter International, and Johnson & Johnson. Eames received her Bachelor of Arts in economics from Northwestern University, Phi Beta Kappa, and her Master of Business Administration from the University of California, Irvine. She serves on the Board of Directors of the Visiting Nurse Service of New York and the Advisory Board of the Smithsonian Libraries, and is a member of the Economic Club of New York.

Ernie Brittingham leads the firm’s Global Healthcare Sector. He is also a core member of the Private Equity and Board & CEO Advisory Partners groups. Brittingham advises Boards, CEO’s, and CHRO’s on board refreshment, de-risking of C-level succession, new company formation and IPO’s, and improving team performance. He most recently led the global Medical Devices and Diagnostics Practice, which more than doubled in both consultants and revenue under his leadership. He has nearly two decades of leadership advisory experience and manages a number of the firm's key global relationships. Brittingham is based in New York. He is known for his integrity, candor, and judgment, and most notably support of executives and companies over decades-long relationships. Brittingham received both his Bachelor of Arts in communications and his Master of Business Administration from Loyola University.

Arthur D. Little’s Healthcare and Life Sciences division in the Central Europe sector is led by Dr. Franziska Thomas, a Partner at the company and innovator in biotechnology research. Prior to beginning her tenure with Arthur D. Little, she distinguished herself with a decade-spanning career that brought her to PA Consulting, McKinsey & Company, and the Dana-Farber Cancer Institute, as well as a remarkable 11 years at Boehringer Ingelheim as a leader in research for oncology and cardiovascular biologic development. Thomas earned a diploma in biochemistry from Universität Witten/Herdecke and a Ph.D. in the same field from ETH Zürich.

Paul Sharma leads Alvarez & Marsal’s European Regulatory Advisory Practice. He specializes in non-routine regulator issues such as investigations, diligence, remediation, business transformation, restructuring, and litigation. His expertise spans financial crime, market conduct, consumer protection, prudential standards, and financial stability. He works across the banking, insurance, payment services, and investment/securities/commodities sectors. His assignments have included work in respect of financial institutions based in (or whose parent is based in) the United Kingdom, the Netherlands, Ireland, Latvia, Lithuania, Estonia, Romania, Bulgaria, the Czech Republic, Germany, Spain, Denmark, Switzerland, Ukraine, Belarus, Russia, Nigeria, Bahrain, Lebanon, and UAE. He was formerly the Deputy Head of the U.K.’s Prudential Regulation Authority, an alternate member of the boards of both the European Banking Authority (EBA) and the European Insurance and Occupational Pensions Authority (EIOPA), and a member of the Basel Committee on Banking Supervision. He earned a Master of Arts in Mathematics from the University of Cambridge.

As the leader of CRA's global Life Sciences practice, Dr. Bell’s business consulting work focuses on the economics of competitive strategy. He works with clients to build sustainable competitive advantages for products, franchises, and brands. These projects have focused on opportunity assessment, product launch, pricing and positioning, marketing strategy, channel management, and resource optimization issues. Dr. Bell has led and consulted projects concerning licensing and valuation, game theory and competitive strategy, capital budgeting and real options, and cost-benefit analyses. Immuno-oncology, rare disease therapeutics, cell and gene therapies, and the relationship among pharmaceuticals, diagnostics, and medtech areas of focus. As an expert witness, Dr. Bell frequently testifies on damages in intellectual property, finance, and antitrust litigation in courts and arbitration proceedings in North America, Europe, Asia, and Australia. Recent expert witness engagements have included assessments of commercially reasonable efforts regarding collaborations and asset purchases in the life sciences industries, including the use of contingent value rights. Dr. Bell brings his experience as a Chartered Professional Accountant in Canada and his expertise as a Master of Business Administration and Ph.D. in Business Economics from Harvard University, where he specialized in strategy and international business, to bear on consulting projects.

Jonathan Kfoury is a Managing Director and Partner with L.E.K. Consulting, a leading global strategy consultancy. He oversees the firm's U.S. Large Biopharma practice, within a broader focus on healthcare and life sciences, and is active within the firm’s Sustainability Centre of Excellence. Kfoury has been involved in the infectious disease space throughout most of his career and has published and spoken extensively across the industry on the global AMR (antimicrobial resistance) crisis, including key initiatives to move it forward. Kfoury is passionate about non-profit efforts in healthcare and serves as an Executive Board member for the Bay Area Global Health Alliance. He has also led a broad range of pro bono projects with L.E.K. focused on helping innovative non-profit organizations grow their societal impact (e.g., Life Sciences Cares). Prior to joining L.E.K., Kfoury held multiple operating roles within biopharma companies, including as manager of global Clinical Development for Cubist’s/Merck’s blockbuster antibiotic Cubicin®. In addition to global management training at INSEAD, Kfoury earned an S.M. in health policy and management from Harvard University and a BS in neuroscience from Trinity College. Outside of work, Kfoury is a jazz aficionado and pianist, and enjoys traveling and getting into the wilderness with his family.

Joe Goldberg is the National Life Sciences Industry Consulting Leader and a Director in the Strategy & Management Consulting practice at RSM, a leading provider of audit, tax, and consulting services to middle-market leaders globally. Goldberg has deep experience working with biopharmaceutical, life science services, and medtech companies that service clients by managing and leading strategic projects that deliver results and create value for the organization. Goldberg’s focus is leading transformation initiatives around event-driven transactions (commercial launch, IPO/SPAC, merger & acquisition integrations, separations/carve-out); target operating model design and execution; business process design, automation, and implementation; enterprise application architecture design and implementation; organizational design and execution; software evaluation and implementation; and complex program and project management. He works with clients through their entire business growth journey to help them stay focused on their scientific innovations and clinical research while working toward meaningful business growth. Joe received his Bachelor of Science from Syracuse University and currently resides in Boston, MA.

Elizabeth (Liz) Levy is a Managing Director for AArete, a global management and technology consulting firm headquartered in Chicago. AArete is a leader in healthcare consulting with experience serving 100+ health plans and 100+ provider organizations. AArete is recognized by Forbes as one of the World’s Best Management Consulting Firms 2022. Levy serves on AArete’s executive leadership team and in her role as a Managing Director she advises healthcare payer clients on strategic profitability improvement, expansion strategies, member experience, and digital and technology initiatives. She has extensive background in strategic cost reduction, scaling payer operations for short- and long-term growth, and using data-driven insights to improve financial and operational performance. Levy leads AArete’s DEI Center of Excellence and is a founding member of AArete’s Women’s Initiative Network (WIN). She is a member of the Women Business Leaders of the U.S. HealthCare Industry Foundation (WBL). Levy holds a BBA in Marketing from Loyola University Chicago and a Master of Business Administration from DePaul University.

Matt Paparella is a tax partner with Crowe LLP, a public accounting and consulting firm headquartered in Chicago, Illinois. Crowe provides tax, audit, advisory, IT, data privacy, and consulting services to life science and healthcare companies. Paparella is an instrumental leader and innovator within Crowe’s life science industry vertical leadership team. This team offers a multitude of accounting and consulting solutions to assist life science companies from business startup and funding, to discovery and development, clinical analysis and regulatory approval, commercialization and production, patient and data management, reporting and governance, and solutioning for incentives to maximize their return on investments. Paparella is a research and development tax incentives specialist. He has extensive experience assisting life science companies with navigating the unique industry challenges including discovery and development, regulatory approval, clinical research, product recalls, corrective/preventive actions, remediation, and FDA actions such as warning letters. Paparella brings over a decade of experience assisting top 20 medtech companies to help make their research investments go further by maximizing and sustaining available incentives, generating $100’s of millions in tax savings for innovative life science companies. He holds a bachelor’s degree in accounting from Grand Valley State University.

As Co-Founder and Senior Managing Director at ToneyKorf Partners, Mark Toney leverages an extensive career in crisis management and operational reorganizations to corporate clients across the healthcare sector and beyond. Under the auspices of this position, he has served as CEO and President of Milford Health and Medical as well as Brookdale University Hospital & Medical Center. Before founding his namesake company in 2012, he worked as national managing partner in corporate recovery and restructuring services for Grant Thornton and was a managing director at AlixPartners for eight years. Toney earned a bachelor’s degree in accounting and finance from West Virginia University.

Ozgur Adigozel is a leader of the Healthcare and Strategy practices at The Boston Consulting Group. He serves leading payers, providers, IDNs, and healthcare services companies on all top-management agenda issues. His primary areas of focus include strategy, growth, business building, personalization, care management, and digital and performance transformations. Adigozel is a seasoned executive with more than two decades of leadership experience. He has deep expertise on the future of healthcare, particularly around the metaverse, personalized experience, digital, advanced analytics, and next-generation care management; proliferation of healthcare delivery, including virtual and home care; and the emergence of new treatments. Prior to joining BCG, he was vice president of marketing and product development at Elevance Health (Anthem). Before Elevance, Adigozel worked at McKinsey and in different management positions at Procter & Gamble. Adigozel earned a Master of Business Administration with high distinction from the University of Michigan business school and received a BS with high distinction in industrial engineering from the Istanbul Technical University. He is a former member of the Turkish Physics Olympics team. Adigozel lives in Chicago with his wife and two children and enjoys reading philosophy, traveling, and sports, and he is a struggling Michigan football fan.

Stephane Budel is more than a founding Partner at Decibio; a seasoned entrepreneur and veteran of the life sciences industry, he has worked to develop the new frontier in genomics and gene sequencing, working with dozens of clients in the research tools and clinical diagnostics fields. In addition to his pioneering work with the firm he launched in 2009, he was the senior life science specialist at L.E.K. Consulting for two years and was founder and chief scientific officer of Living Rox, Inc. Budel holds a master’s degree in physiology from the University of Geneva and a Ph.D. in neurology from Yale University.

Ray Pressburger is a Managing Director leading an end-to-end business within Accenture Life Sciences focused on accelerating and supporting all aspects of product commercialization. The practice brings together deeply strategic management consulting with a broad array of technology, agency, and operations services to shape and evolve commercial organizations within the industry. Pressburger has held successive leadership roles within Accenture since 2005, with a historical core focus on strategy work with life sciences brand and portfolio teams prior to leading the end-to-end business. In his time at Accenture, Pressburger has worked with nearly every major life sciences company on product or enterprise level programs and touched nearly every dimension of commercialization. Pressburger is an alumni of Lehigh University with a Bachelor of Science in industrial and systems engineering.

Kris Vilamaa is a Partner and Chief Growth Officer for Mostly Medicaid. Mostly Medicaid is one of the premier Medicaid consulting and marketing entities in the country, using best-in-class HHS expertise to help state and county government agencies, health plans, and solution providers to navigate a wide variety of challenges. In this role, Vilamaa has led engagements in twenty-three different states with hundreds of clients in his career. His experience includes improving existing solutions, bringing new solutions to market, driving innovation, stakeholder engagement, industry analyses, growth strategy development, change management, policy assessments, and operational assessments. Vilamaa is a national thought leader on information technology in behavioral health and the use of data in integrated care models to improve care. As a consultant, he has also served as the CEO of HealthCare Perspective and Director of Behavioral Health for Germane Solutions. Prior to entering consulting in 2015, Vilamaa served in state government for 15 years, the last three as the Chief Information Officer for the Alabama Department of Mental Health. He holds a Bachelor of Art in Political Science from Purdue University-West Lafayette.

Stéphane Bazoche is a Partner at Monitor Deloitte, the multinational strategy consulting practice of Deloitte, formerly The Monitor Group. Monitor Deloitte’s strategy practitioners combine deep industry insights with cutting-edge methods to help leaders resolve their most critical decisions, drive value, and achieve transformational success. In his role as Partner, Bazoche is a life sciences expert focused on biopharma and medtech products, global launches, commercial marketing, market access, and pricing strategies development. He is also Head of the Monitor Deloitte French office and leads Deloitte Strategy, Analytics, and M&A activities in Continental Europe. Since he joined Monitor in 2010, he has developed specific expertise in value optimization of life sciences products, driving the strategic and design choices for superior value recognition and access conditions from indication selection, to clinical trial design, to market access and pricing strategy. In addition, he drives Deloitte Consulting France ESG activities development and supports leading pharma clients in enhancing their social impact with a focus on patient access to medicines.

Dr. Ulrica Sehlstedt is a Managing Partner in Arthur D. Little’s Stockholm office and Global Practice Leader for Healthcare and Life Sciences. Since joining ADL in 2007, Sehlstedt has worked extensively for clients across the healthcare and life sciences ecosystem, helping them to succeed in a changing business environment driven by scientific advancements, disruptive technologies, and industry convergence. Her experience includes growth strategy development, opportunity assessment, R&D effectiveness, operational and commercial due diligence, change management, and program management. Before joining ADL, Sehlstedt was the CEO of a molecular diagnostics start-up. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years and served as a member of the 2007 and 2016 national expert panels in Life Science Technologies for Future Research Leaders, a program launched by the Swedish Foundation for Strategic Research. Sehlstedt holds an MSc in chemical engineering from the Chalmers University of Technology and a Ph.D. in biophysics from Stockholm University.

Shantanu Baruah is an Executive Vice President leading New Business acquisition in the Life Sciences and Healthcare business at HCL Technologies. Prior to this, he actively spearheaded one of HCL’s top three accounts globally and headed the digital practice. With over 21+ years of experience across multiple disciplines, Baruah has been a pioneer in the fields of healthcare, life sciences, digital, and information access at HCL Technologies. His leadership has guided delivery, practice building, and development of market-leading solutions to reach new heights. A leader with global exposure, Baruah has successfully led teams across India, Singapore, France, and the U.S. His technological expertise and innovative leadership qualities have placed him at the forefront of important business acquisitions. A passionate writer, he has authored numerous papers on healthcare, knowledge management, digital experience management, and big data impact on payers/providers. Baruah is also an active speaker at industry forums. Baruah is active in the app development community and has an approved app on the Apple App Store. Shantanu has been recognized as one of The top 25 Healthcare IT Executives of 2020 by The IT Services Report. Baruah lives in NJ. His philanthropic outreach includes education for children in developing nations.

In her role as Managing Director and Partner at L.E.K. Consulting, Sheila Shah specializes in delivering next-level outcomes within the fields of growth strategy and M&A in the healthcare and medtech industries. She has built her tireless work in this area in her nearly seven years with the company in its Chicago office, leading its Global Women’s Network Committee and co-authoring numerous articles on artificial intelligence and consumerism in healthcare. Shah earned a bachelor’s degree in economics and political science from Barnard College and holds a Master of Business Administration from Northwestern University’s Kellogg School of Management.

Dr. Subbu Ramanarayanan chairs NERA’s Health Care Antitrust practice and is an Adjunct Associate Professor of Competitive Strategy at UCLA Anderson School of management. Dr. Ramanarayanan has extensive experience advising clients on antitrust reviews of proposed mergers and acquisitions before the Federal (FTC and DOJ) and State antitrust agencies across a variety of settings in health care including hospital services, health insurance, physician services, medical devices, and Healthcare IT services. He is particularly experienced in the analysis of large and complex health care provider transactions, including addressing horizontal, vertical, and cross-market issues raised by antitrust agencies in such matters. Recently, Dr. Ramanarayanan testified on behalf of the merging parties in the FTC’s challenge of the merger between Albert Einstein Health Network and Thomas Jefferson University, which was the first time the FTC lost a hospital merger challenge in nearly two decades. He was also the lead economist retained by counsel for the merging parties in the formation of Beth Israel Lahey Health, a complex multi-billion dollar transaction involving five merging hospital systems that was ultimately cleared by the Federal Trade Commission after an in-depth investigation. Dr. Ramanarayanan also has an active practice focused on litigation around liability and damages issues in health care antitrust and has analyzed issues pertaining to market definition and market power, alleged monopolization, monopsony, exclusive contracting, price-fixing, tying, bundling, and alleged foreclosure in various healthcare markets.

Tian Han is a Managing Director and Partner at L.E.K., a company for which he has helped drive the strategy of the world’s top pharmaceutical and biotech companies for more than a decade. His wide base of expertise in healthcare strategy was built over the years he spent before joining L.E.K., during which he served as a consultant to Amylin Pharmaceuticals and worked for the business development and marketing department of Kythera Biopharmaceuticals. Han received a bachelor’s degree in biology from Gonzaga University, and he went on to earn a master’s degree in bioscience business from the Keck Graduate Institute.

Colm Foley has spent 31 years in the consulting industry, the last 23 with the Boston Consulting Group. As a Managing Director & Senior Partner with BCG, Foley has held senior leadership roles including Global Leader of the Medical Technology Sector and Leader of the Healthcare Practice, North America. His consulting work has focused on enabling leading medical technology and pharmaceutical companies to drive breakout growth, including bringing innovative diagnostics and therapies to market, transforming commercial capabilities, digitizing products and processes, and driving successful high-value mergers and acquisitions. Foley will join Blackstone Lifesciences this fall. BXLS is a leading alternative investment fund that brings vital, but underfunded healthcare products to market by funding and executing late-stage development. As a Managing Director, Foley will help lead investments in the medical technology sector (devices, diagnostics, and life sciences tools) and in this role continue to partner with leading firms to successfully launch innovative products that improve patient care and outcomes. Foley started his career as a technical architect with Andersen Consulting. He holds a Bachelor of Arts from University of Michigan, and a Master of Business Administration from University of Chicago.